Disgren (triflusal) / Uriach Pharma - LARVOL DELTA

Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VELAZQUEZ-EPIC26 study. (PubMed, Cardiovasc Revasc Med) - "In a large real-world population undergoing PCI for native coronary artery, a new hydrodynamic ultra-thin strut SES with abluminal permanent fluoropolymer containing triflusal shows low TLF and very low ST rates at 2 years."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Thrombosis

ROLE OF TRIFLUSAL AS A THERAPEUTIC OPTION IN STROKE SECONDARY PREVENTION STRATEGY (ESOC 2025) - "Being a 4-trifluoromethyl derivative of salicylate, Triflusal is structurally related to Aspirin and is known to reduce platelet aggregation by inhibiting thromboxane A2 production. A larger, prospective clinical trial is needed to verify aforementioned results and also to establish the place of Triflusal in TIA/stroke secondary prevention strategy."

Cardiovascular • Ischemic stroke • Myocardial Infarction

Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack: A Network Meta-Analysis of Randomized Controlled Trials (AAN 2025) - "Ticagrelor had a higher mortality risk than triflusal (RR 2.44; 95% CI 1.03–5.76). Aspirin+clopidogrel, aspirin+cilostazol, aspirin, cilostazol, and tirofiban lowered END in patients with IS or TIA. Aspirin+clopidogrel increased mortality compared with aspirin+dipyridamole, clopidogrel, and triflusal. Tirofiban was found to be best in reducing END and triflusal for mortality."

Retrospective data • Cardiovascular • Ischemic stroke

Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. (PubMed, Int J Mol Sci) - "The antiplatelet drugs aspirin and triflusal, inhibitors of cyclooxygenase-1 (COX-1); ticagrelor, an inhibitor of the receptor P2Y12; vorapaxar, an inhibitor of the PAR-1 receptor, were combined with DHA or EPA and evaluated against in vitro platelet aggregation induced by agonists arachidonic acid (AA), adenosine diphosphate (ADP) and TRAP-6. We further investigated procaspase-activating compound 1 (PAC-1) binding and P-selectin membrane expression in platelets stimulated with ADP and TRAP-6...The antiplatelet drugs exhibited heterogeneity regarding their effect on P-selectin and αIIbβ3 membrane expression, while both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though had no effect on P-selectin expression induced by ADP or TRAP-6. The combinatory effect of DHA and EPA with the antiplatelet drugs did not result in enhanced inhibitory activity compared to the sum of the individual effects of each component."

Journal • Preclinical • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Inflammation • Metabolic Disorders

NSAIDs, analgesics, antiplatelet drugs, and decline in renal function: a retrospective case-control study with SIDIAP database. (PubMed, BMC Pharmacol Toxicol) - "We observed a decline in renal function associated with metamizole and antiplatelet agent, especially triflusal, and with high use of acetic acid derivates, Coxibs, and major opioids. Further studies are necessary to confirm these results."

Journal • Retrospective data • Cardiovascular • Diabetes • Hypertension • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology

Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study. (PubMed, Rev Esp Cardiol (Engl Ed)) - "Triflusal use appears to increase the risk of susceptibility to COVID-19 infection and an even higher risk of hospitalization, whereas the other antiplatelets could be associated with a reduction in the risk of the various outcomes or have no effect on risk. These findings could support reconsideration of triflusal prescription in COVID-19 pandemic situations."

Journal • Cardiovascular • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Unravelling the potential of Triflusal as an anti-TB repurposed drug by targeting replication protein DciA. (PubMed, Microbes Infect) - "Four drugs namely Lanreotide, Risedronate, Triflusal, and Zoledronic acid showed higher molecular docking scores. Our findings present novel DciA inhibitors and anti-TB activity of Triflusal. Further investigations on the use of Triflusal may lead to the discovery of a new anti-TB drug."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

In silico identification of molecular mechanisms for stroke risk caused by heavy metals and their mixtures: sponges and drugs involved. (PubMed, Neurotoxicology) - "Triflusal and andrographolide have been identified as potential treatments for heavy metal-induced stroke. Taken together, heavy metals may be a significant contributor to the pathophysiology of stroke, but further investigation into the precise molecular pathways implicated in stroke pathophysiology is required to corroborate these findings."

Journal • Cardiovascular • Inflammation • APOA1 • IL1B • IL6 • MIR124-2 • MIR155 • MIR26A1 • NFKB2 • NF-κβ • NOS2 • NR1I2

Effect of Chronic Antiplatelet and Anticoagulant Medication in Neck Haematoma and Perioperative Outomes After Carotid Endarterectomy. (PubMed, Ann Vasc Surg) - "Double antiaggregation and anticoagulation did not confer better perioperative outcomes after elective CEA in our study. These regimens were associated with increased risk of neck haematoma, especially severe bleeding, with similar rates of neurologic events in both symptomatic and asymptomatic patients and no mortality benefit. Monotherapy with aspirin appears to be the safest perioperative antithrombotic regimen for elective CEA."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Antiplatelet regimens for Asian patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. (PubMed, Ann Transl Med) - "A total of 84,103 patients from 32 studies were included: patients in used aspirin (n=26,834); cilostazol (n=3,303); clopidogrel (n=12,406); prasugrel (n=1,885); sarpogrelate (n=752); ticagrelor (n=1,933); ticlopidine (n=1,644); triflusal (n=391); aspirin plus cilostazol (n=1,120), aspirin plus clopidogrel (n=4,623); aspirin plus dipyridamole (n=10,853); aspirin plus ticagrelor (n=5,859); aspirin plus ticlopidine (n=132). Clustered three-dimensional rank plots of recurrent stroke, major bleeding, and composite vascular events demonstrated that cilostazol had higher values of the surface under the cumulative ranking curve than other treatments. Of the antiplatelet regimens, cilostazol showed the best net clinical benefits than other antiplatelet regimens in Asians with non-cardioembolic stroke or TIA."

Journal • Retrospective data • Review • Cardiovascular • Ischemic stroke

First in man evaluation of a sirolimus-eluting stent with abluminal fluoropolymeric/triflusal coating with ultrathin struts by OCT at 9 months follow up. The PROMETHEUS study. (PubMed, Cardiovasc Revasc Med) - "In this study the ihtDEStiny stent has shown a very low degree of neointimal proliferation associated with a low rate of uncovered/malapposed struts and total absence of subclinical thrombi at 9 months follow up."

Clinical • Journal • Cardiovascular • Hematological Disorders • Thrombosis

Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized Controlled Trial. (PubMed, Nutrients) - "We evaluate whether participants of the PREvención con DIeta MEDiterránea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HR: 4.22 [1.92-9.30], HR: 1.71 [0.83-3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors."

Clinical • Journal • Cardiovascular

Photosensitivity to Triflusal. (PubMed, J Allergy Clin Immunol Pract) - No abstract available

Journal

Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. (PubMed, Sci Rep) - "Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract. Preliminary examination in the unilateral 6-hydroxydopamine-lesioned rat revealed a modest but significant protection against nigral cell loss with both drugs. Our data demonstrate the power of targeted repositioning as a method to identify existing drugs that may combat disease progression in Parkinson's by boosting FGF20 levels."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

[VIRTUAL] Omega-3 Fatty Acids Significantly Improve the Antiplatelet Profile of Triflusal (ISTH 2020) - "DHA significantly improves Triflusal's inhibitory effect towards AA-induced platelet aggregation, whereas in the presence of EPA, Triflusal expresses a potent inhibitory effect towards TRAP-6-induced platelet activation. The underlying mechanisms and the importance of these findings at the clinical level, in patients treated with Triflusal for the secondary prevention of ischemic events, need further investigation."

Reperfusion Injury • F2

Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. (PubMed, Curr Vasc Pharmacol) - P4 | "The efficacy of triflusal in the secondary prevention of vascular events is similar to aspirin when administered for 12 months. Importantly, triflusal significantly reduced the incidence of ΜΙ and showed a better safety profile compared with aspirin. (ASpirin versus Triflusal for Event Reduction In Atherothrombosis Secondary prevention, ASTERIAS trial; Clinical Trials.gov Identifier: NCT02616497)."

Clinical • Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Myocardial Infarction • Thrombosis

"Triflusal 600mg plus clopidogrel 75mg" (@DAthanasias)

Photobinding of Triflusal to Human Serum Albumin Investigated by Fluorescence, Proteomic Analysis, and Computational Studies. (PubMed, Front Pharmacol) - "Docking and molecular dynamic simulation studies reveal that HTB supramolecular binding to HSA occurs in the "V-cleft" region and that the process is assisted by the presence of Glu/Asp residues in the neighborhood of the external Lys, in agreement with the experimentally observed modifications. In principle, photobinding can occur with other trifluoroaromatic compounds and may be responsible for the appearance of undesired photoallergic side effects."

Journal